Vetr upgraded shares of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) from a buy rating to a strong-buy rating in a research note issued to investors on Wednesday morning. Vetr currently has $5.93 price objective on the biopharmaceutical company’s stock.
A number of other equities analysts have also commented on the company. Maxim Group reiterated a buy rating and issued a $9.00 price objective (up from $7.00) on shares of Keryx Biopharmaceuticals in a research note on Friday, July 8th. Zacks Investment Research upgraded Keryx Biopharmaceuticals from a hold rating to a buy rating and set a $8.00 price target on the stock in a research note on Wednesday, July 13th. FBR & Co restated a buy rating and set a $13.00 price target on shares of Keryx Biopharmaceuticals in a research note on Monday, July 25th. Stifel Nicolaus lowered Keryx Biopharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, August 2nd. Finally, Brean Capital lowered Keryx Biopharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, August 2nd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $8.44.
Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) opened at 4.63 on Wednesday. Keryx Biopharmaceuticals has a 1-year low of $2.80 and a 1-year high of $7.80. The stock has a 50 day moving average price of $4.86 and a 200-day moving average price of $5.47. The firm’s market cap is $490.29 million.
Keryx Biopharmaceuticals (NASDAQ:KERX) last released its quarterly earnings data on Monday, August 1st. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.14. The firm had revenue of $9.30 million for the quarter, compared to analyst estimates of $8.60 million. Keryx Biopharmaceuticals had a negative net margin of 590.50% and a negative return on equity of 172.04%. Keryx Biopharmaceuticals’s revenue for the quarter was up 272.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.26) EPS. On average, equities research analysts expect that Keryx Biopharmaceuticals will post ($1.24) earnings per share for the current fiscal year.
In other Keryx Biopharmaceuticals news, CFO Scott A. Holmes sold 4,935 shares of the company’s stock in a transaction on Friday, July 29th. The shares were sold at an average price of $7.36, for a total transaction of $36,321.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.08% of the stock is currently owned by corporate insiders.
Hedge funds have recently modified their holdings of the stock. Alpine Partners VI LLC acquired a new stake in shares of Keryx Biopharmaceuticals during the second quarter valued at approximately $110,000. Trexquant Investment LP acquired a new stake in shares of Keryx Biopharmaceuticals during the second quarter valued at approximately $115,000. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Keryx Biopharmaceuticals by 38.2% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 18,100 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 5,000 shares during the last quarter. LMR Partners LLP acquired a new stake in shares of Keryx Biopharmaceuticals during the second quarter valued at approximately $125,000. Finally, Stifel Financial Corp acquired a new stake in shares of Keryx Biopharmaceuticals during the second quarter valued at approximately $170,000. Institutional investors own 61.15% of the company’s stock.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.